Date: 2014-09-17
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the 2014 Congress of the European Society for Medical Oncology (ESMO)
Company: Eisai (Japan)
Product: Halaven® (eribulin)
Action
mechanism: Eribulin is a non-taxane, microtubule dynamics inhibitor indicated for the treatment of patients with breast cancer who have previously received at least two chemotherapeutic regimens for metastatic disease and whose prior therapy should have included an anthracycline and a taxane. Eribulin belongs to a class of antineoplastic agents, the halichondrins, which are natural products, isolated from the marine sponge Halichondria okadai. It is believed to work by inhibiting the growth phase of microtubule dynamics without affecting the shortening phase and sequesters tubulin into non-productive aggregates.
Disease: metastatic breast cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On September 17, 2014, Eisai announced that nine abstracts for Eisai's oncology portfolio are to be presented during the European Society for Medical Oncology (ESMO) 2014 Congress, inMadrid, Spain between 26 and 30 September, 2014. - Impact of treatment with eribulin or capecitabine for Eribulin metastatic breast cancer on EQ-5D utility derived from EORTC QLQ-C30. Abstract No: 1046P Poster Display Session - Efficacy of eribulin in a second-line or later setting in patients with metastatic breast cancer: a pooled Eribulin analysis. Abstract No: 393P Poster Display Session - HRQOL and disease symptoms in patients with locally advanced or metastatic breast cancer treated with eribulin or capecitabine in a post anthracycline and Eribulin taxane setting. Abstract No: 392P Poster Display Session
Data to be presented include three abstracts for Halaven® (eribulin):
